COX-2 expression in fibroblast aggregates as a functional indicator for the anti-inflammatory activity of leukemia patients' bone marrow-derived hematopoietic cells.
Reciprocal communication between hematopoietic cells and their surrounding bone marrow stroma is crucial for normal progression of hematopoiesis. This complex network of cell-to-cell signals in the microenvironment involves both cell contact-mediated and paracrine cues. In hematological malignancies the intricate balance is, however, disrupted to support cancer progression. In order to detect altered microenvironmental reactivity of a hematopoietic cell sample, cellular functional assays can be designed to measure the cells' capacity to modulate stromal stress reactions, such as inflammation.Recently, we showed that human leukemic cell lines of monocytic origin can actively participate in modulation of stromal inflammation. In order to further functionally evaluate the hematopoietic cells' capacity to modulate stromal inflammation, we utilized an in vitro model of nemosis-induced inflammation of fibroblasts in a three-dimensional culture setting. This process of stromal inflammation in fibroblast aggregates is consistent, requires both cell-contact and paracrine signals, and can be produced on a large scale to support dose-dependent analyses. To extend our previous observations, we evaluated the effect of a wide panel of leukemia cell lines on cyclooxygenase- 2 induction in fibroblast aggregates in co-culture. We also assessed the feasibility of the model to support clinical functional testing by utilizing the hematopoietic fraction of leukemia patients' bone marrow aspirates after immunophenotyping. Our results suggest that the stromal inflammation-modulating activity of these samples is differently modulated in cancer and in normal bone marrow. Moreover, differences in the samples' anti-inflammatory activity may reflect disease state.
Cancer Research Institute, Slovak Academy of Sciences, Bratislava, Slovakia. katarina.egyudova@savba.sk
K
K
Egyudova
M
M
Fajtova
A
A
Cizmar
M
M
Korhonen
J
J
Gyarfas
E
E
Kankuri
J
J
Bizik
D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000378:metabolism*; D001853:Bone Marrow / Q000201:enzymology / Q000276:immunology / Q000473:pathology*; D002450:Cell Communication; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D018920:Coculture Techniques; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D020405:Dermis / Q000201:enzymology / Q000276:immunology / Q000473:pathology; D005260:Female; D005347:Fibroblasts / Q000201:enzymology / Q000276:immunology / Q000473:pathology*; D005434:Flow Cytometry; D006412:Hematopoietic Stem Cells / Q000201:enzymology / Q000276:immunology / Q000473:pathology*; D006801:Humans; D015151:Immunoblotting; D016130:Immunophenotyping; D007223:Infant; D007938:Leukemia / Q000201:enzymology / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D017154:Stromal Cells / Q000201:enzymology / Q000276:immunology / Q000473:pathology; D059016:Tumor Microenvironment; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human